Drug Trial Radar · NCT07907120
Cost-Effectiveness of Upfront Supplemental Anaesthesia in Symptomatic Irreversible Pulpitis
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
234
Planned (sponsor's estimate)
Start
Oct 30, 2026
Primary completion
May 30, 2027
Study completion Jun 15, 2027
Sponsor
- Lead sponsor
- Jamia Millia IslamiaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Health services research
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn whether giving extra (supplemental) local anaesthetic injections at the start of treatment, rather than only after the standard injection fails, makes numbing of painful lower molar teeth more successful and lowers the overall cost of care in adults with symptomatic irreversible pulpitis (a severe toothache caused by an inflamed nerve) attending a public-sector dental hospital in India. The main questions it aims to answer are: * Does adding an articaine buccal infiltration, alone or together with an intraligamentary injection, to the standard inferior alveolar nerve block (IANB) increase the number of patients who can have their root canal treatment started without pain and without rescue injections? * What is the extra cost per additional successful anaesthesia of each upfront strategy compared with IANB followed by rescue injections only when needed? Researchers will compare three groups: IANB with rescue injections only if needed (control), IANB plus upfront articaine buccal infiltration, and IANB plus upfront articaine buccal infiltration and intraligamentary injection. Participants will: * Receive a standard IANB, followed (depending on their group) by one or two additional injections before treatment starts * Rate their pain during access and cleaning of the tooth on a visual analogue scale; rescue injections will be given if pain is moderate or severe * Have the time taken and the injections used recorded by an independent observer * Answer a short questionnaire about travel, time and earnings lost for each visit * Receive a phone call 24 hours later about pain and any side effects
Conditions
- Irreversible Pulpitis
- Anesthesia, Local
Interventions
Inferior Alveolar Nerve Block With 2% Lidocaine With 1:80,000 AdrenalineDrug
Conventional IANB with 1.8 mL 2% lidocaine with 1:80,000 adrenaline, 27-gauge long needle, injected over about 60 seconds after 60 seconds of topical 20% benzocaine. Lip numbness checked at 15 minutes; the IANB is repeated once if absent. Given to all participants before allocation is revealed.
Upfront Buccal Infiltration With 4% Articaine With 1:100,000 AdrenalineDrug
1.8 mL 4% articaine with 1:100,000 adrenaline given as buccal infiltration opposite the root apices of the study tooth after lip numbness from the IANB is confirmed and before access; access begins after 5 minutes.
Upfront Intraligamentary Injection With 2% Lidocaine With 1:80,000 AdrenalineDrug
Intraligamentary injection of 0.2 mL 2% lidocaine with 1:80,000 adrenaline at each of the mesial and distal roots (0.4 mL total) using a 30-gauge short needle with firm back-pressure, given after the articaine buccal infiltration and before access; access begins after 5 minutes.
Standardised Stepwise Rescue Anaesthesia LadderProcedure
Triggered when the patient reports pain above 54 mm on the 170-mm Heft-Parker VAS, or asks to stop, during access or instrumentation. Steps already given in the allocated arm are skipped: (1) articaine buccal infiltration 1.8 mL; (2) intraligamentary injection 0.2 mL per root; (3) intrapulpal injection 0.2-0.4 mL under pressure; (4) session abandoned, analgesic prescribed, temporary dressing placed and visit rebooked within 7 days. Intraosseous injection is not used. Total dose stays within weight-based maximum limits.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Initial-Strategy Anaesthetic SuccessTime frame: Perioperative
- Incremental Cost-Effectiveness Ratio (Public-Provider Perspective)Time frame: Day 1
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Jamia Millia Islamia
New Delhi, National Capital Territory of Delhi, India
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.